

**NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE**

**Review Proposal of NICE Technology Appraisal Guidance No. 96,153 & 154 on the use of adefovir dipivoxil, peginterferon alfa-2a, entecavir and telbivudine for the treatment of hepatitis B**

**Matrix of consultees and commentators**

<b>Consultees</b>	<b>Commentators (no right to submit or appeal)</b>
<p><u>Manufacturers/sponsors</u></p> <ul style="list-style-type: none"> <li>• Bristol-Myers Squibb Pharmaceuticals (entecavir)</li> <li>• Novartis Pharmaceuticals UK (telbivudine)</li> <li>• Gilead Sciences (adefovir dipivoxil)</li> <li>• Roche Products (interferon alfa 2a, peginterferon alfa 2a)</li> <li>• Schering-Plough (interferon alfa 2a, interferon alfa 2b)</li> </ul> <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> <li>• Afiya Trust</li> <li>• Age Concern England</li> <li>• AVERT</li> <li>• Black Health Agency</li> <li>• British Liver Trust</li> <li>• British Organ Donor Society</li> <li>• British Viral Hepatitis Group</li> <li>• Chinese National Healthy Living Centre</li> <li>• Compass UK</li> <li>• Confederation of Indian Organisations</li> <li>• Counsel and Care</li> <li>• Drugs Action</li> <li>• Equalities National Council</li> <li>• GMFA - The Gay Men's Health Charity</li> <li>• Haemophilia Alliance</li> <li>• Haemophilia Society</li> <li>• Help the Aged</li> <li>• Hepatitis A -Z</li> <li>• Hepatitis B Foundation UK</li> <li>• Mainliners</li> <li>• Muslim Council of Great Britain</li> </ul>	<p><u>General</u></p> <ul style="list-style-type: none"> <li>• Age Concern Cymru</li> <li>• Board of Community Health Councils in Wales</li> <li>• British National Formulary</li> <li>• Department of Health, Social Services and Public Safety for Northern Ireland</li> <li>• Medicines and Healthcare products Regulatory Agency</li> <li>• National Association of Primary Care</li> <li>• National Public Health Service for Wales</li> <li>• NHS Alliance</li> <li>• NHS Confederation</li> <li>• NHS Purchasing and Supply Agency</li> <li>• NHS Quality Improvement Scotland</li> <li>• Scottish Medicines Consortium</li> </ul> <p><u>Comparator manufacturer(s)</u></p> <ul style="list-style-type: none"> <li>• Gilead Sciences (adefovir dipivoxil)</li> <li>• Roche Products Limited (interferon alfa 2a, peginterferon alfa 2a)</li> <li>• Schering-Plough Ltd (interferon alfa 2a, interferon alfa 2b)</li> <li>• Bristol-Myers Squibb Pharmaceuticals Ltd (entecavir)</li> <li>• Novartis Pharmaceuticals UK Ltd (telbivudine)</li> </ul> <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> <li>• Foundation for Liver Research</li> <li>• MRC Clinical Trials Unit</li> <li>• National Institute for Health Research</li> <li>• Policy Research Institute on Ageing and</li> </ul>

National Institute for Health and Clinical Excellence

Matrix of consultees and commentators for the Review Proposal of NICE Technology Appraisal Guidance No. 96,153 & 154 on the use of adefovir dipivoxil, peginterferon alfa-2a for the treatment of hepatitis B

Issue date: April 2009

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> <li>• Muslim Health Network</li> <li>• Positively Women</li> <li>• South Asian Health Foundation</li> <li>• Specialised Healthcare Alliance</li> <li>• Transplant Support Network</li> <li>• Youth Net</li> </ul> <p><u>Professional groups</u></p> <ul style="list-style-type: none"> <li>• Association of Clinical Microbiologists</li> <li>• Association of Medical Microbiologists</li> <li>• Association of Nurses in Substance Abuse</li> <li>• British Association for Services to the Elderly</li> <li>• British Association for the Study of the Liver</li> <li>• British Association for the Study of the Liver Nurses Forum</li> <li>• British Association of Sexual Health and HIV</li> <li>• British Geriatrics Society</li> <li>• British Infection Society</li> <li>• British Liver Nurses Forum</li> <li>• British Society of Blood &amp; Marrow Transplantation</li> <li>• British Society of Gastroenterology</li> <li>• British Transplantation Society</li> <li>• Haemophilia Nurses Association</li> <li>• Health Protection Agency</li> <li>• Hepatitis Nurse Specialist Forum</li> <li>• Infection Control Nurses Association</li> <li>• Medical Foundation for AIDS &amp; Sexual Health</li> <li>• Royal College of Anaesthetists</li> <li>• Royal College of General Practitioners</li> <li>• Royal College of Nursing</li> <li>• Royal College of Pathologists</li> <li>• Royal College of Physicians</li> <li>• Royal College of Surgeons</li> <li>• Royal Pharmaceutical Society</li> <li>• Royal Society of Medicine – Intellectual Disabilities Forum</li> <li>• Society for General Microbiology</li> </ul>	<p>Ethnicity</p> <ul style="list-style-type: none"> <li>• Research Institute for the Care of Older People</li> <li>• UCL Centre for Sexual Health &amp; HIV Research</li> <li>• United Kingdom Clinical Research Network</li> </ul> <p><u>Evidence Review Group</u></p> <ul style="list-style-type: none"> <li>• Southampton Health Technology Assessment Centre, University of Southampton</li> <li>• National Institute for Health Research Health Technology Assessment Programme</li> </ul> <p><u>Associated Guideline Groups</u></p> <ul style="list-style-type: none"> <li>• None</li> </ul> <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> <li>• None</li> </ul>

National Institute for Health and Clinical Excellence  
 Matrix of consultees and commentators for the Review Proposal of NICE Technology Appraisal Guidance No. 96,153 & 154 on the use of adefovir dipivoxil, peginterferon alfa-2a for the treatment of hepatitis B

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> <li>• UK Clinical Virology Network</li> <li>• UK Haemophilia Centre Doctors' Organisation</li> <li>• United Kingdom Clinical Pharmacy Association</li> </ul> <p><u>Others</u></p> <ul style="list-style-type: none"> <li>• Department of Health</li> <li>• Western Cheshire PCT</li> <li>• Barnet PCT</li> <li>• Welsh Assembly Government</li> </ul>	

NICE is committed to promoting equality and eliminating unlawful discrimination.

Please let us know if we have missed any important organisations from the lists contained within the matrix and which organisations we should include who have a particular focus on relevant equality issues.

***PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS***

### Definitions:

#### Consultees

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Assembly Government and relevant NHS organisations in England.

The manufacturer/sponsor of the technology is invited to make an evidence submission, respond to consultations and has the right to appeal against the Final Appraisal Determination (FAD).

All non-manufacturer/sponsor consultees are invited to submit a statement<sup>1</sup>, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

#### Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; NHS Quality Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Information Authority and NHS Purchasing and Supplies Agency, and the *British National Formulary*).

All non-manufacturers/sponsors commentators are invited to nominate clinical specialists or patient experts.

#### Assessment team

An independent academic group (commissioned by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme) to assist in the appraisal) prepares an Assessment Report on the health technology (a review of the clinical and cost effectiveness of the technology(ies) based on a systematic review of the literature and a review of manufacturer and sponsor submission to the Institute).

---

<sup>1</sup> Non manufacturer consultees are invited to submit statements relevant to the group they are representing.

